Investigational drug · Phase 2
DAT-2645
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "DAT-2645"
First trial start
2026
Jun 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DAT-2645", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DAT-2645" as an intervention, largest first.
Danatlas Pharmaceuticals Co., LtdIndustry
NCT06614751 · 112 participants (planned) · Start Nov 1, 2024 · Primary completion Nov 1, 2026
Drug: DAT-2645 tablet; DAT-2645 tablet · For: Solid Cancers; BRCA Mutation; HRD Cancer and 8 more
Sites: Beijing, China; Beijjing, China
- A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian CancerNot yet recruiting
Danatlas Pharmaceuticals Co., LtdIndustry
NCT07652073 · 30 participants (planned) · Start Jun 15, 2026 · Primary completion Nov 30, 2027
Drug: DAT-2645 tablet · For: Advanced or Metastatic Ovarian Cancer
Sites: Guangzhou, China; Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.